NDA 021468 · Takeda Pharms USA
Fosrenol
Lanthanum Carbonate · Oral
NovelLast checked: Nov 20, 2026Latest source record: Aug 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Oct 26, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
44
13 Phase 3, 0 recruiting
FAERS reports
5,132
4,599 serious, 1,612 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2025.
LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). ( 1 )
Mechanism: LANTHANUM CARBONATE is a phosphate binder that reduces absorption of phosphate by forming insoluble lanthanum phosphate complexes that pass through the GI tract unabsorbed. Both serum phosphate and calcium phosphate product are reduced as a consequence of the reduced dietary phosphate absorption.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
4 products under this application
- FOSRENOL · LANTHANUM CARBONATE EQ 500MG BASE · TABLET, CHEWABLE, ORAL · Prescription · TE AB
- FOSRENOL · LANTHANUM CARBONATE EQ 750MG BASE · TABLET, CHEWABLE, ORAL · Prescription · TE AB
- FOSRENOL · LANTHANUM CARBONATE EQ 250MG BASE · TABLET, CHEWABLE, ORAL · Discontinued
- FOSRENOL · LANTHANUM CARBONATE EQ 1GM BASE · TABLET, CHEWABLE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Lanthanum Carbonate" as an intervention, any sponsor and status, largest first.
ShireTakeda (TAK)
NCT00160121 · 2,500 participants · Start Jan 10, 2005 · Primary completion Dec 13, 2005
Drug: Lanthanum carbonate · For: Kidney Failure, Chronic
- Outcome Study of Lanthanum Carbonate Compared With Calcium Carbonate in Hemodialysis Patients : Landmark StudyPivotal-lookingCompleted
Translational Research Center for Medical Innovation, Kobe, Hyogo, JapanAcademic, hospital or other
NCT01578200 · 2,309 participants · Start Dec 24, 2011 · Primary completion Mar 25, 2019
Drug: Lanthanum Carbonate; Calcium Carbonate · For: Hemodialysis; Hyperphosphatemia
Sites: Shinagawa, Japan
- Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum CarbonatePivotal-lookingTerminated
Ineos Healthcare LimitedIndustry
NCT00841126 · 657 participants (planned) · Start Jul 2009 · Primary completion Jul 2011
Drug: Magnesium iron hydroxycarbonate; Lanthanum carbonate and 1 more · For: Chronic Kidney Failure
Sites: Birmingham, Alabama; Phoenix, Arizona; Tempe, Arizona · 112 sites in all
- Efficacy and Safety of Lanthanum in Controlling Serum Phosphate Levels in Subjects With End Stage Renal Disease Who Require Treatment for High Levels of Phosphate in Their BloodPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00150566 · 460 participants · Start Feb 9, 2004 · Primary completion Oct 8, 2005
Drug: Lanthanum carbonate · For: Kidney Failure, Chronic
- Efficacy and Tolerability of Treatment With Lanthanum Carbonate in Patients With End Stage Renal Disease Receiving DialysisPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00151931 · 456 participants · Start May 11, 2004 · Primary completion Jan 12, 2006
Drug: Lanthanum carbonate · For: Kidney Failure, Chronic
- Phase III Double-blind Comparative Study of BAY77-1931 (Lanthanum Carbonate) With Calcium CarbonatePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01514851 · 259 participants · Start Jan 2006 · Primary completion May 2006
Drug: Lanthanum carbonate (BAY77-1931); Calcium carbonate · For: Hyperphosphatemia
Sites: Toyohashi, Japan; Yatomi, Japan; Asahi, Japan · 31 sites in all
- The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidEPivotal-lookingCompleted
The Cleveland ClinicAcademic, hospital or other
NCT02258074 · 205 participants · Start Mar 2015 · Primary completion Nov 2018
Drug: Nicotinamide; Lanthanum Carbonate and 2 more · For: Chronic Kidney Disease
Sites: San Diego, California; Denver, Colorado; Washington D.C., District of Columbia · 7 sites in all
- Head to Head Study Against Sevelamer HydrochloridePivotal-lookingCompleted
ShireTakeda (TAK)
NCT00441545 · 182 participants · Start Jan 5, 2007 · Primary completion Jul 31, 2008
Drug: Fosrenol (Lanthanum Carbonate); Sevelamer hydrochloride · For: Chronic Kidney Disease, Stage 5
Sites: Mesa, Arizona; Phoenix, Arizona; Tempe, Arizona · 44 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death679
- nausea504
- vomiting492
- constipation386
- sepsis381
- abdominal pain375
- off label use351
- general physical health deterioration348
- abdominal distension320
- hyponatraemia311
- multiple organ dysfunction syndrome300
- anaemia297
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 68 |
| 2006 | 87 |
| 2007 | 76 |
| 2008 | 112 |
| 2009 | 296 |
| 2010 | 496 |
| 2011 | 309 |
| 2012 | 290 |
| 2013 | 214 |
| 2014 | 202 |
| 2015 | 254 |
| 2016 | 279 |
| 2017 | 284 |
| 2018 | 297 |
| 2019 | 258 |
| 2020 | 269 |
| 2021 | 329 |
| 2022 | 273 |
| 2023 | 218 |
| 2024 | 209 |
| 2025 | 169 |
| 2026 | 143 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fosrenol (Lanthanum Carbonate)
2024 spending
$5.3M
Beneficiaries
1,090
3,262 claims
Per beneficiary
$4,861
$11.44 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,656,274 |
| 2021 | $5,669,795 |
| 2022 | $5,242,536 |
| 2023 | $5,765,884 |
| 2024 | $5,298,907 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Isaka Y, Hamano T, Fujii H, et al. · J Am Soc Nephrol 2021 · Multicenter Study, Randomized Controlled Trial
- Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H, Fukagawa M, Hirakata H, et al. · JAMA 2021 · Comparative Study, Multicenter Study
- Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients.
Zeng Q, Zhong Y, Yu X · Ren Fail 2023 · Meta-Analysis, Review
- Effects of lanthanum carbonate and calcium carbonate on cardiovascular calcification in hemodialysis patients: A systematic review and meta-analysis.
Yang J, Zhang X, Wang L · Clin Nephrol 2022 · Meta-Analysis, Systematic Review
- Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide.
Jiang M, Zheng H, Xu C, et al. · J Nanosci Nanotechnol 2020 · Meta-Analysis
- The phosphate binder equivalent dose.
Daugirdas JT, Finn WF, Emmett M, et al. · Semin Dial 2011 · Research Support, N.I.H., Extramural, Systematic Review
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.